Verve Therapeutics (VERV) Competitors $4.50 -0.05 (-1.10%) (As of 10:17 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends VERV vs. KNSA, TVTX, NTLA, SYRE, PRAX, OCUL, DAWN, RCUS, SPRY, and SAVAShould you be buying Verve Therapeutics stock or one of its competitors? The main competitors of Verve Therapeutics include Kiniksa Pharmaceuticals (KNSA), Travere Therapeutics (TVTX), Intellia Therapeutics (NTLA), Spyre Therapeutics (SYRE), Praxis Precision Medicines (PRAX), Ocular Therapeutix (OCUL), Day One Biopharmaceuticals (DAWN), Arcus Biosciences (RCUS), ARS Pharmaceuticals (SPRY), and Cassava Sciences (SAVA). These companies are all part of the "pharmaceutical products" industry. Verve Therapeutics vs. Kiniksa Pharmaceuticals Travere Therapeutics Intellia Therapeutics Spyre Therapeutics Praxis Precision Medicines Ocular Therapeutix Day One Biopharmaceuticals Arcus Biosciences ARS Pharmaceuticals Cassava Sciences Verve Therapeutics (NASDAQ:VERV) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, community ranking, institutional ownership, risk, earnings, media sentiment, dividends and valuation. Which has stronger earnings & valuation, VERV or KNSA? Kiniksa Pharmaceuticals has higher revenue and earnings than Verve Therapeutics. Kiniksa Pharmaceuticals is trading at a lower price-to-earnings ratio than Verve Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVerve Therapeutics$11.76M32.68-$200.07M-$2.46-1.85Kiniksa Pharmaceuticals$270.26M5.66$14.08M-$0.14-151.27 Do analysts rate VERV or KNSA? Verve Therapeutics presently has a consensus price target of $25.75, suggesting a potential upside of 467.18%. Kiniksa Pharmaceuticals has a consensus price target of $36.60, suggesting a potential upside of 72.80%. Given Verve Therapeutics' higher probable upside, equities research analysts clearly believe Verve Therapeutics is more favorable than Kiniksa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verve Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Kiniksa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, VERV or KNSA? Verve Therapeutics has a beta of 1.75, meaning that its stock price is 75% more volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500. Does the MarketBeat Community favor VERV or KNSA? Kiniksa Pharmaceuticals received 146 more outperform votes than Verve Therapeutics when rated by MarketBeat users. Likewise, 64.89% of users gave Kiniksa Pharmaceuticals an outperform vote while only 53.33% of users gave Verve Therapeutics an outperform vote. CompanyUnderperformOutperformVerve TherapeuticsOutperform Votes2453.33% Underperform Votes2146.67% Kiniksa PharmaceuticalsOutperform Votes17064.89% Underperform Votes9235.11% Do institutionals and insiders believe in VERV or KNSA? 97.1% of Verve Therapeutics shares are held by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals shares are held by institutional investors. 19.3% of Verve Therapeutics shares are held by company insiders. Comparatively, 54.6% of Kiniksa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media prefer VERV or KNSA? In the previous week, Verve Therapeutics had 3 more articles in the media than Kiniksa Pharmaceuticals. MarketBeat recorded 3 mentions for Verve Therapeutics and 0 mentions for Kiniksa Pharmaceuticals. Verve Therapeutics' average media sentiment score of 0.76 beat Kiniksa Pharmaceuticals' score of 0.49 indicating that Verve Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Verve Therapeutics Positive Kiniksa Pharmaceuticals Neutral Is VERV or KNSA more profitable? Kiniksa Pharmaceuticals has a net margin of -2.36% compared to Verve Therapeutics' net margin of -807.65%. Kiniksa Pharmaceuticals' return on equity of -7.31% beat Verve Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Verve Therapeutics-807.65% -35.23% -27.65% Kiniksa Pharmaceuticals -2.36%-7.31%-5.95% SummaryKiniksa Pharmaceuticals beats Verve Therapeutics on 10 of the 17 factors compared between the two stocks. Ad Wyatt Investment ResearchMy #1 Pre IPO Trade for 2025 – NAME and TICKEROne tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...The Next SpaceX Pre-IPO Get Verve Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VERV vs. The Competition Export to ExcelMetricVerve TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$384.36M$6.48B$5.07B$8.80BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-1.854.9789.5613.60Price / Sales32.68371.451,224.8087.40Price / CashN/A52.5939.4536.27Price / Book0.7610.306.976.33Net Income-$200.07M$153.61M$119.04M$225.93M7 Day Performance-15.61%-1.73%-1.78%-0.96%1 Month Performance-18.20%-7.26%-3.59%1.06%1 Year Performance-60.31%31.10%31.64%26.59% Verve Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VERVVerve Therapeutics2.4352 of 5 stars$4.50-1.1%$25.75+472.2%-63.2%$380.97M$11.76M-1.83110KNSAKiniksa Pharmaceuticals1.9939 of 5 stars$20.81-1.9%$36.60+75.9%+33.9%$1.50B$270.26M0.00220TVTXTravere Therapeutics3.0581 of 5 stars$18.21+2.0%$22.62+24.2%+210.6%$1.42B$145.24M0.00460NTLAIntellia Therapeutics4.5389 of 5 stars$13.90+5.9%$54.94+295.2%-56.7%$1.42B$36.28M-2.58600Analyst ForecastAnalyst RevisionSYRESpyre Therapeutics2.3417 of 5 stars$27.18-1.2%$48.57+78.7%N/A$1.40B$890,000.000.00100News CoveragePRAXPraxis Precision Medicines1.7647 of 5 stars$72.86-1.1%$146.33+100.8%+299.3%$1.36B$2.45M0.00110OCULOcular Therapeutix3.7464 of 5 stars$8.60-2.1%$16.71+94.4%+273.6%$1.35B$58.44M0.00267DAWNDay One Biopharmaceuticals2.0003 of 5 stars$13.40-1.6%$35.71+166.5%+12.4%$1.35BN/A0.0060Positive NewsRCUSArcus Biosciences2.6831 of 5 stars$14.29-2.3%$34.00+137.9%+4.7%$1.31B$117M0.00500SPRYARS Pharmaceuticals2.734 of 5 stars$13.36-1.4%$24.00+79.6%+183.5%$1.30B$30,000.000.0090Analyst RevisionSAVACassava Sciences3.8385 of 5 stars$26.91+3.3%$111.50+314.3%+59.6%$1.29BN/A-18.8830 Related Companies and Tools Related Companies Kiniksa Pharmaceuticals Competitors Travere Therapeutics Competitors Intellia Therapeutics Competitors Spyre Therapeutics Competitors Praxis Precision Medicines Competitors Ocular Therapeutix Competitors Day One Biopharmaceuticals Competitors Arcus Biosciences Competitors ARS Pharmaceuticals Competitors Cassava Sciences Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VERV) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verve Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verve Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VERV Stock Alerts